Abstract
Patients with a clinical diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) were randomised in a double-blind, placebo-controlied multicentre trial to investigate whether high-dose intravenous immunoglobulin treatment (IVIg) for ried out in a group of selected patients it is still unclear if all newly diagnosed patients judged to have CIDP in whom no other therapy has been started will respond to IVIg. This was investigated in a double-blind randomised placebo controlled multicentre trial.
Methods
Criteria for eligibility Patients eligible for this study were admitted with symptoms and signs of polyneuropathy in the absence of systemic disease, with an electrophysiological diagnosis of demyelinating polyneuropathy based on slowed nerve conduction velocities and or conduction blocks, increased CSF protein (more than 05 g/l) and progression of weakness exceeding eight weeks. It was necessary for patients to have a normal erythrocyte sedimentation rate (ESR), haematocrit, white cell and platelet count, serum creatinine, serum glucose, normal liver and thyroid function tests, no antinuclear antibodies, cryoglobulin, or monoclonal protein and also a normal chest radiograph. Patients with a kinship history of neuropathy were excluded as were patients on immunosuppressive treatment. For inclusion in the study all patients required a disability of at least 3 on the modified Rankin scale." This is a six point scale: 0 = asymptomatic, 1 = nondisabling symptoms which do not interfere with lifestyle, 2 -minor disability symptoms, which lead to some restriction of lifestyle, but do not interfere with the patients' capacity to look after themselves, 3 = moderate disability symptoms which significantly interfere with lifestyle or prevent totally independent existence, 4 = moderately severe disability symptoms which clearly prevent independent existence, but do not require constant attention day and night, 5 = severely disabled, totally dependent, requiring constant attention day and night. Randomisation When a patient was eligible and after informed consent, the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service Amsterdam (CLB) was informed. The CLB supplied either bottles with immunoglobulin or placebo for a complete treatment course, Improvement after trial treatment was defined as at least a one point decrease on the Rankin scale and no improvement as unchanged or increased scoring on the Rankin scale. The same neurologist did the first and the last evaluation.
We aimed at randomising 28 patients. This number of patients was based on the assumption that at least half of the patients in the treatment group would improve and none in the placebo group. The ethics committees of the participating centres approved the study protocol. Differences between the groups were analysed with Fisher's exact probability test.
Results
Twenty eight patients who fulfilled the clinical, physiological and CSF criteria for the diagnosis CIDP"3 were entered into the trial; 15 were treated with IVIg and 13 with placebo. 
Discussion
In this study in newly diagnosed patients with CIDP who had no other therapy, we could not demonstrate a beneficial effect of IVIg treatment. This lack of beneficial effect cannot be explained by the method of measuring treatment effect. Improvement was defined as at least a one point decrease on the Rankin scale which is a clinically important improvement. It might be that smaller improvements were not detected by using this scale. Using a more sensitive scale, the MRC sum score, we were also unable to detect differences between the groups.
The interobserver agreement of both the Rankin scale and the MRC sum score has been investigated and appeared to be good.'0 14 Moreover, the same neurologist did the first and last evaluation. Furthermore, a different method, electrophysiological studies, could not detect differences between the groups.
The assessment of treatment response was not carried out too late as none of the patients had initially improved and had deteriorated just before the assessment of treatment response.
A surprising finding was that rapid and dramatic improvement occurred within days after trial treatment in some patients of the placebo group. These patients had a slowly progressive neuropathy of 4 to 6 months duration and after administration of placebo, improvement followed at a rate far faster than the rate of deterioration before the trial treatment. All three patients recovered and needed no repeated treatment. The course in these patients was monophasic, with an onset as in CIDP and recovery as in the Guillain-Barre syndrome. A similar course has recently been described in another report. '5 We do not believe that improvement in these patients can be ascribed to an active compound in the placebo preparation since such an effect was not seen in the cross-over study in CIDP patients. 18 Spontaneous improvements in CIDP patients have already been described in the 1 950s; Austin described the typical course of untreated patients with CIDP in whom the peak of disability was slowly reached after approximately five months.'6 From a plateau of disability, these patients then gradually improved and Austin commented that this recovery phase period invariably took longer than the onset of the illness. Dramatic and rapid improvements in CIDP patients treated with IVIg were therefore attributed by us to this treatment. Discovering after the trial code had been broken that some patients in the placebo group had improved rapidly and clinically significantly, we even considered an error in the trial treatment administration. Serum samples taken before and after treatment, however, showed that none of the patients treated with placebo had an increase in serum immunoglobulin level. Today we have little experiences of the natural course of CIDP in patients with marked disability as these patients are usually treated with corticosteroids or with plasma exchange. If the patients who were randomised to placebo had not participated in this trial, they would probably have been treated with high-dose prednisone for prolonged periods, as rapid reduction of the prednisone dose is not recommended because this is considered to carry a great risk of breakthrough of the disease."' The spontaneous and rapid improvement of some CIDP patients observed in this study shows that at least some of these patients may be treated too long with a treatment which is not without risks.
This study included only 28 patients, therefore a type II error should be considered. In calculating the required number of patients, we did not consider the possibility of dramatic improvements in the placebo group. Our hypothesis was that patients in the placebo group would have no clinical significant improvements within two weeks and that at least half of the patients in the treatment group would improve. We calculated that 28 patients would be sufficient to test this hypothesis. Furthermore, in previous studies this number of patients was sufficient to demonstrate treatment efficacy in CIDP. 2 3 This small study does not exclude effectiveness of IVIg in CIDP, but we may conclude that this treatment is less effective than we had presumed. In a previous study we found improvement after IVIg in 32 of 52 patients (62%; 95% confidence limits 47_75). 18 In this study only 4 of 15 patients improved (27%; 95% confidence limits 8-55); a lower figure, although not significantly since the 95% confidence intervals overlap. A similar low figure has recently been found in an open study on IVIg treatment; improvement in strength or functional tasks was demonstrated in only 3 of 15 CIDP patients. 9 Recently, research criteria for the diagnosis of CIDP have been published.'3 All our patients fulfilled the clinical, physiological and CSF criteria for the diagnosis of CIDP, but not the pathological features since nerve biopsy was not required for entry into the study and had rarely been carried out. All the patients, therefore, can be classified as probable CIDP. It is unlikely that nerve biopsy would have changed the diagnosis in many of these patients. In an analysis of a group of 52 patients treated with IVIg we found five simple factors that were related to improvement": progression of weakness until treatment, absence of discrepancy in weakness between arms and legs, disease duration less than one year, areflexia of the arms, and motor NCV of the median nerve less than 80% of the lower limit of normal. It was calculated that the probability of improvement after IVIg is 93% if all these factors are present in a patient with a clinical diagnosis of CIDP. In this study 10 patients in the placebo group and only 6 patients in the IVIg group including the 4 responders, fulfilled these 5 criteria. Prospective studies are needed to investigate if these criteria are useful in the selection of patients who may benefit from IVIg treatment.
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